Authors: Papadopoulou, MV Ji, M Bloomer, WD

Citation: Mv. Papadopoulou et al., Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice, CANC CHEMOT, 48(2), 2001, pp. 160-168

Authors: Deutsch, M Gerszten, K Bloomer, WD Avisar, E

Citation: M. Deutsch et al., Lumpectomy and breast irradiation for breast cancer arising after previousradiotherapy for Hodgkin's disease or lymphoma, AM J CL ONC, 24(1), 2001, pp. 33-34

Authors: Blumenthal, RD Taylor, A Osorio, L Ochakovskaya, R Raleigh, JA Papadopoulou, M Bloomer, WD Goldenberg, DM

Citation: Rd. Blumenthal et al., Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia, INT J CANC, 94(4), 2001, pp. 564-571

Authors: Papadopoulou, MV Ji, M Rao, MK Bloomer, WD

Citation: Mv. Papadopoulou et al., 4-[3-(2-nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo:Comparison with tirapazamine, ONCOL RES, 12(8), 2000, pp. 325-333

Authors: Papadopoulou, MV Ji, M Rao, MK Bloomer, WD

Citation: Mv. Papadopoulou et al., 4-[3-(2-nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin, ONCOL RES, 12(4), 2000, pp. 185-192

Authors: Papadopoulou, MV Ji, M Khan, SH Bloomer, WD

Citation: Mv. Papadopoulou et al., Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro, ONCOL RES, 11(8), 1999, pp. 345-357